1,295 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Mario Gabelli Comments on TNT Express NV http://www.gurufocus.com/news/388372/mario-gabelli-comments-on-tnt-express-nv Jan 29, 2016 - Mario Gabelli Comments on TNT Express NV, Stocks: TNTE, Mario Gabelli, release date:Jan 29, 2016
Gilead Sciences' Stake In Galapagos NV Is Not A Game Changer http://seekingalpha.com/article/3771186-gilead-sciences-stake-in-galapagos-nv-is-not-a-game-changer?source=feed_all_articles Dec 22, 2015 - Gilead Sciences announced they have taken an equity stake in Galapagos NV.The move is an interesting one, Galapagos lead product is outside the field of oncology.The article below will examine the dea
LyondellBasell Industries NV (LYB) Bhavesh V. Patel on Q3 2015 Results - Earnings Call Transcript http://seekingalpha.com/article/3599516-lyondellbasell-industries-nv-lyb-bhavesh-v-patel-on-q3-2015-results-earnings-call-transcript?source=feed_tag_transcripts Oct 23, 2015 - LyondellBasell Industries NV (NYSE:LYB)Q3 2015 Earnings CallOctober 23, 2015 11:00 am ETExecutivesDouglas J. Pike - Vice President, Investor RelationsBhavesh V. Patel - Chief Executive Officer & Chair
Mylan NV Presents at Morgan Stanley Healthcare Brokers Conference (Transcript) http://seekingalpha.com/article/3518926-mylan-nv-presents-at-morgan-stanley-healthcare-brokers-conference-transcript?source=feed_tag_transcripts Sep 17, 2015 - Mylan NV (NASDAQ:MYL) Morgan Stanley Healthcare Conference Call September 17, 2015 2:40 PM ET Executives Heather Bresch - Chief Executive Officer John Sheehan - CFO, EVP, Principal Financial & Acc
Merck KGaA Intends to File for Approval of MS Drug in EU http://www.zacks.com/stock/news/189996/merck-kgaa-intends-to-file-for-approval-of-ms-drug-in-eu?cid=CS-ZC-FT-189996 Sep 14, 2015 - Merck KGaA (MKGAF) announced that it has submitted a letter of intent to the EMA to file a marketing authorization application for MS candidate, cladribine.
Mylan NV Makes Tender Offer for Perrigo http://www.zacks.com/stock/news/189983/mylan-nv-makes-tender-offer-for-perrigo?cid=CS-ZC-FT-189983 Sep 14, 2015 - Mylan NV continues aggressive bid for fellow generic drug maker Perrigo with a tender offer to shareholders.
Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer http://www.zacks.com/stock/news/189800/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer?cid=CS-ZC-FT-189800 Sep 11, 2015 - Aduro (ADRO) signed a clinical study agreement with Incyte (INCY) to evaluate CRS-207, in combination with Incyte's epacadostat, in patients with ovarian cancer.
Novartis' Farydak Gets EU Approval for Multiple Myeloma http://www.zacks.com/stock/news/189134/novartis-farydak-gets-eu-approval-for-multiple-myeloma?cid=CS-ZC-FT-189134 Sep 07, 2015 - Novartis' (NVS) Farydak (plus Velcade and dexamethasone) gets EU approval for relapsed and/or refractory multiple myeloma in treatment-experienced patients.
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Amgen, Novartis Team Up; Bone Drug Positive in Phase III http://www.zacks.com/stock/news/188757/amgen-novartis-team-up-bone-drug-positive-in-phase-iii?cid=CS-ZC-FT-188757 Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.

Pages: 1...124125126127128129130

<<<Page 129